Head and Neck Cancers Coverage From Every Angle

Recent News

Use of Minimally Invasive Biopsy for Early-Stage Oral Cancer
2019 ASCO-SITC: Tumor Growth Rate and Outcomes With Nivolumab in Head and Neck Cancer
2019 ASCO-SITC Symposium: Regulatory T Cells and Treatment Resistance in Head/Neck Cancer
2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index
Is Incidence of Thyroid Cancer in United States Related to Malpractice Climate?
FDA Grants Priority Review to Pembrolizumab in First-Line Therapy for Metastatic Head/Neck Cancer
Gene Mutations by Smoking Status in Head and Neck Cancer
Using Genetic Biomarker to Predict Outcome in HPV-Related Oropharyngeal Cancer
KEYNOTE-040 Supports Benefit of Pembrolizumab in Resistant Head and Neck Cancer
Oropharyngeal Cancer and Opioid Use
Phase II Durvalumab Trial in Resistant Head and Neck Cancer
Is HPV on the Rise in Oropharyngeal Cancers?
Radiotherapy Plus Chemotherapy in HPV-Positive Oropharyngeal Cancer
Early Study of Lestaurtinib in Anaplastic Thyroid Cancer
Five-MicroRNA Signature: Predicting Outcomes in HPV-Negative Head and Neck Cancer
Human Papillomavirus and Pathways to Oncogenesis
Post Hoc Analysis of Pembrolizumab Versus Standard of Care in Head and Neck Cancer
FDA Approves Larotrectinib in Solid Tumors With NTRK Gene Fusion
Intensity-Modulated Radiotherapy for Head and Neck Squamous Cell Carcinomas
ESMO 2018: Neoadjuvant Olaparib in Squamous Cell Head and Neck Carcinoma
ASTRO 2018: Cetuximab Versus Cisplatin for HPV-Related Head and Neck Cancer
Low-Dose Radioiodine Ablation and Recurrence of Thyroid Cancer
Evaluating Recombinant Human Thyrotropin Use in Patients With Thyroid Cancer
ASTRO 2018: Liquid Biopsy for Detecting Recurrence of HPV-Related Oropharyngeal Cancer
FDA Permits Marketing of Two Devices to Assist Thyroid Imaging During Surgery
ESMO 2018: Pembrolizumab Monotherapy for Resistant Head and Neck Cancer
ASTRO 2018: Chemoradiation Therapy for High-Risk Oral Squamous Cell Carcinoma
ESMO 2018: Chemoradiotherapy in HPV-Positive Oropharyngeal Cancer
Patient-Partnered Genomics Study of Immunotherapy for Angiosarcoma
FDA Grants Breakthrough Therapy Designation to LOXO-292 in Thyroid Cancer
ATA 2018: Preclinical Study of Novel Compound in Anaplastic Thyroid Cancer
ATA 2018: Are Suspicious and Malignant Thyroid Nodules Inadequately Evaluated?
ATA 2018: Larotrectinib for Thyroid Cancer With NTRK Fusions
MTHFR Gene Polymorphisms and Oral Squamous Cell Carcinoma
Quality Care Symposium: Speech Pathology Referrals in Head and Neck Cancer
Early Study of Evofosfamide in HPV-Negative Head and Neck Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.